SCIENTIFIC PUBLICATIONS
. . . . . .
Acute Hemodynamic Improvement in Chronic Pulmonary Arterial Hypertension on Dual Therapy Following RT234-PAH Inhalation
PULMONARY HYPERTENSION ASSOCIATION MEETING (PHA 2022)
JUNE 9-12, 2022
Keogh A, Dwyer N, Kotlyar E, Kaye D.
Safety and Efficacy of RT234 Vardenafil Inhalation Powder on Exercise Parameters in pulmonary Arterial Hypertension: Phase 2b, Dose-Escalation Study Design
PULMONARY HYPERTENSION ASSOCIATION MEETING (PHA 2022)
JUNE 9-12, 2022
Benza R, Franco V, Aras M, Spikes L, Grinnan D, Satler C.
Acute Hemodynamic Improvement in Chronic Pulmonary Arterial Hypertension on Dual Therapy Following RT234-PAH Inhalation.
Chest Annual Meeting 2020.
October 18–21, 2020
Keogh A, Dwyer N, Kotlyar E, Kaye D, Maurer M, Weers J, Parsley E.
Safety and Pharmacokinetics of Vardenafil Inhalation Powder (RT234-PAH) Following Oral Inhalation in Healthy Adult Volunteers.
Chest Annual Meeting 2020.
October 18–21, 2020
Parsley EL, Weers J, Tarara, T, Eldon M, TepperJ, Maurer M.
Design of a Capsule-Based Dry Powder Inhaler for PAH Patients: The AOS™ DPI.
Formulation & Delivery Series U.S.: Virtual.
September 29-30, 2020
Lyons S, Weers J.
Inspiratory Flow Profiles of PAH Patients with AOS™ Device Intended to Administer Inhaled Vardenafil.
ERS International Congress 2020.
September 7–9, 2020
Sahay S, Holy R, Lyons S, Parsley E, Maurer M, Weers J.
The AOS™ DPI: A Capsule-Based Dry Powder Inhaler with Four Distinct Dispersion Elements.
Respiratory Drug Delivery (Digital RDD) 2020 Conference.
April 26–June 30, 2020
Weers J, Lyons S, Tarara T, Miller DP, Molloy L, Weers A, Saavedra K, Heller D, Curtis R.
Increased Packing Density of Fine Particles in Spray-Dried Formulations.
Respiratory Drug Delivery (Digital RDD) 2020 Conference.
April 26–June 30, 2020
Weers JG, Miller DP.
The Confusing World of Dry Powder Inhalers: It is All About Inspiratory Pressures, Not Inspiratory Flow Rates.
J. Aerosol Med. Pulm. Drug Deliv. (2020) 33:1-11.
2020
Clark AR, Weers JG, Dhand R.
Post-Inhalation Cough with Therapeutic Aerosols: Formulation Considerations.
Adv. Drug Deliv. Rev.
2020
Sahakijpijarn W, Smyth H, Miller D, Weers J.
Idealhalers Versus Realhalers: Is it Possible to Bypass Deposition in the Upper Respiratory Tract?
J. Aerosol Med. Pulm. Drug. Deliv. (2019) 32:55-69.
2019
Weers JG, Son YJ, Glusker M, Haynes A, Huang D, Kadrichu N, Le J, Li X, Malcolmson R, Miller DP, Tarara TE, Ung K, Clark A.
Is Aerodynamic Diameter a Good Metric for Understanding Regional Deposition?
Respiratory Drug Delivery (RDD) Europe 2019 Conference.
2019
Weers J, Rao N, Kadrichu N.
Comparison of Phospholipid-Based Particles for the Delivery of Ciprofloxacin in Bronchiectasis Patients.
Pulm Ther. (2019) 5:127–150.
2019
Weers JG.
Spray-Dried Formulations for Inhalation Comprising Crystalline Drug Powders.
AAPS PharmSci. Tech.
2019
Weers JG, Miller DP, Tarara TE.
An Add-on to Dry Powder Inhaler Device that Can Improve Dose Delivery to the Lungs.
RDD Europe
2017
Yin J, Bovet J-M, Smyth H, Clark A, Hannon J.
Accessorized DPI: a Shortcut Towards Flexibility and Patient Adaptability in Dry Powder Inhalation.
Drug Delivery to the Lungs (DDL) Conference
2016
Buttini F, Hannon J, Saavedra K, Rossi I, Balducci AG, Smyth H, Clark A, Colombo P.
Accessorized DPI: a Shortcut Towards Flexibility and Patient Adaptability in Dry Powder Inhalation.
Pharm Res. 2016. 33(12): 3012-3020.
2016
Buttini F, Hannon J, Saavedra K, Rossi I, Balducci AG, Smyth H, Clark A, Colombo P.
Novel High Efficiency Inhaler for PDE5i Lung Delivery.
Respiratory Drug Delivery (RDD)
2016
Hannon J, Donovan M, Gibbons A, Xu Z, Curtis R, Smyth HD, Clark AR.
Novel Low Resistance DPI for High Efficiency Delivery in a Broad Range of Drug Classes.
Respiratory Drug Delivery (RDD)
2012
Donovan MJ, Gibbons A, Pappo J, Smyth HDC.
In Vivo Lung Deposition Feasibility Study Comparing the Respira AOS DPITM to the Handihaler® in Human Subjects.
Respiratory Drug Delivery (RDD)
2012
Gibbons A, Zeman KL, Bennett WD, Pappo J, Smyth HDC, Donovan MJ.
Novel Dual-Chamber Dry Powder Inhaler for Combination Therapy.
American Association of Pharmaceutical Scientists (AAPS) Annual Meeting
2011
Donovan MJ, Gibbons A, Smyth HDC, Pappo J.
Aerosol Performance of Large Drug-Coated Beads Across Multiple Inhalation Flow Rates.
American Association of Pharmaceutical Scientists (AAPS) Annual Meeting
2011
Donovan MJ, Gibbons A, Smyth HDC, Pappo J.
Phase 2 clinical trials of our leading pipeline candidate are underway
. . . . . .
Respira’s lead drug-device product candidate, RT234-PAH, is a first-in-class inhaled therapy intended for as-needed (PRN) use by patients experiencing symptoms. This contrasts with all other current PAH treatments, which are taken according to a chronic treatment regimen.